Reference isolates of Talaromyces marneffei

 

Talaromyces marneffei (previously known as Penicillium marneffei) causes talaromycosis, a globally significant, endemic fungal infection that is fatal if left untreated in disseminated infections. The disease primarily affects immunocompromised individuals, especially those living with HIV/AIDS in Southeast Asia, Southern China, and Northeast India. Even with antifungal treatment, talaromycosis has an estimated mortality rate of 30% (1). In a multicenter clinical trial comparing itraconazole and amphotericin B, approximately 25% of patients experienced poor outcomes, defined as prolonged hospitalization, disease relapse, or death .2

Until recently, research into antifungal resistance in T. marneffei was challenging due to the absence of standardized susceptibility testing guidelines. A 2023 report addressed this gap by establishing methods for evaluating antifungal drugs against T. marneffei clinical isolates 3. BEI Resources now offers two reference clinical isolates, NR-60072 and NR-60073, which were included in the study and previously sequenced using whole-genome sequencing 4. These isolates will support the standardization of antifungal assays and screening of new therapeutic compounds against talaromycosis.

  

BEI Item No.

Now available from BEI Resources

NR-60072 Talaromyces marneffei, 03-130
NR-60073 Talaromyces marneffei, 20-091

  

Left panel, colonies of Talaromyces marneffei 03-130 (NR-60072) growing on potato dextrose agar. Right panel, light microscopy of yeast cells of NR-60072 growing at 37 °C showing oval to ellipsoidal morphology with a central dividing septum.

 

References:

1. Narayanasamy S., et al. “A Global Call for Talaromycosis to be Recognised as a Neglected Tropical Disease.” Lancet Glob. Health. 9 (2021): e1618-e1622. PubMed: 34678201.

2. Le T., et al. “A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis.” N. Engl. J. Med. 376 (2017): 2329-2340. PubMed: 28614691.

3. Thu N.T.M., et al. “Development and Validation of a Colorimetric Antifungal Susceptibility Testing Method for the Dimorphic Fungus Talaromyces marneffei.” Med. Mycol. 61 (2023): myad111. PubMed: 37994652.

4. Cuomo C.A., et al. “Complete Genome Sequences for Two Talaromyces marneffei Clinical Isolates from Northern and Southern Vietnam.” Microbiol. Resour. Announc. 9 (2020): e01367-19. PubMed: 31919177.

 

Image Alt Text: Left panel, colonies of Talaromyces marneffei 03-130 (NR-60072) growing on potato dextrose agar. Right panel, light microscopy of yeast cells of NR-60072 growing at 37 °C showing oval to ellipsoidal morphology with a central dividing septum. (BEI Resources)

Image Credit: Colonies and light microscopy of T. marneffei. (BEI Resources)

View More Highlights